C
Carlo Avolio
Researcher at University of Foggia
Publications - 78
Citations - 2024
Carlo Avolio is an academic researcher from University of Foggia. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 21, co-authored 66 publications receiving 1740 citations. Previous affiliations of Carlo Avolio include University of Bari.
Papers
More filters
Journal ArticleDOI
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes
Carlo Avolio,Maddalena Ruggieri,Fabrizio Giuliani,Grazia Maria Liuzzi,R. Leante,Paolo Riccio,Paolo Livrea,Maria Trojano +7 more
TL;DR: Results show that an increase in MMP-2/TIMP-2 ratio marks chronic progression in MS, but it is as high as in HC, and also confirm that high M MP-9 activity characterizes short duration relapsing and active forms of the disease.
Journal ArticleDOI
Age-related disability in multiple sclerosis.
Maria Trojano,Maria Liguori,G. B. Zimatore,Roberto Bugarini,Carlo Avolio,Damiano Paolicelli,Fabrizio Giuliani,Francesca De Robertis,Maria Giovanna Marrosu,Paolo Livrea +9 more
TL;DR: The results of the current study demonstrate the impact of age on rate of disability progression in multiple sclerosis and suggest that an age‐adjusted progression index may be a more relevant criterion for defining differences between multiple sclerosis groups.
Journal ArticleDOI
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.
TL;DR: The clinical data of 309 patients with definite multiple sclerosis were recorded in the European data base for multiple sclerosis (EDMUS) to determine the prognostic significance of several demographic and clinical variables.
Journal ArticleDOI
Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis
Maria Trojano,Fabio Pellegrini,Damiano Paolicelli,A Fuiani,G. B. Zimatore,C. Tortorella,Isabella Laura Simone,Francesco Patti,A. Ghezzi,Valentina Zipoli,Paolo Rossi,Carlo Pozzilli,Giuseppe Salemi,Alessandra Lugaresi,Roberto Bergamaschi,Enrico Millefiorini,Marinella Clerico,Giacomo Lus,M. Vianello,Carlo Avolio,Paola Cavalla,Vito Lepore,Paolo Livrea,G. Comi,M. P. Amato +24 more
TL;DR: Evaluating the effectiveness of early IFNβ treatment in definite relapsing‐remitting MS and the optimal time to initiate IFN β treatment with regard to the greatest benefits on disability progression to support greater efficacy of early vs. delayed interferon beta treatment.
Journal ArticleDOI
Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS
Maria Trojano,Carlo Avolio,Grazia Maria Liuzzi,Maddalena Ruggieri,G. Defazio,Maria Liguori,Maria Pia Santacroce,Damiano Paolicelli,Fabrizio Giuliani,Paolo Riccio,Paolo Livrea +10 more
TL;DR: Results show that rIFNbeta-1b therapy increases sICAM-1 serum levels and reduces serum MMP-9 activity.